Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns.
The KDIGO 2024 CKD guideline updates the 2012 guidance using a substantially broader evidence base, emphasising risk-based evaluation and newer kidney-protective therapies for people with chronic kidney disease not on dialysis or transplant.
Background
The KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease updates the 2012 guideline, developed with patient partners, clinicians, and researchers worldwide using GRADE methodology. It applies to adults and children with CKD who are not receiving dialysis or a kidney transplant.
Key recommendations
The update emphasises greater use of cystatin C for estimating glomerular filtration rate, an individualised risk-based approach to predicting kidney failure, sodium-glucose cotransporter-2 inhibitors for some patients with CKD with and without diabetes, and statin use for adults older than 50 years with CKD. The accompanying synopsis notes the full guideline contains 28 recommendations and 141 practice points, also supporting point-of-care testing in remote areas.
Clinical implications
The guideline covers evaluation and risk assessment, management to delay progression and complications, medication management and drug stewardship, and optimal models of CKD care. Practice points direct clinical activities where systematic review was not feasible, and the document highlights both 'known knowns' and a research agenda addressing remaining evidence gaps.
Category
KDIGO
Source
Kidney Int
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.